Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Viridian Therapeutics, Inc. Trends and Insights

Biotech SG&A Expenses: Growth Strategies Unveiled

__timestampSarepta Therapeutics, Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 2014493150007751000
Thursday, January 1, 20157504300010251000
Friday, January 1, 2016837490009575000
Sunday, January 1, 201712268200010912000
Monday, January 1, 201820776100011049000
Tuesday, January 1, 201928481200011646000
Wednesday, January 1, 202031787500013265000
Friday, January 1, 202128266000025805000
Saturday, January 1, 202245142100035182000
Sunday, January 1, 202348187100094999000
Loading chart...

Infusing magic into the data realm

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and Viridian Therapeutics, Inc. over the past decade. From 2014 to 2023, Sarepta's SG&A expenses surged by over 870%, reflecting its aggressive growth strategy. In contrast, Viridian's expenses increased by approximately 1,125%, albeit from a much smaller base, indicating its rapid expansion phase.

Key Insights

  • Sarepta Therapeutics: Starting at $49 million in 2014, expenses peaked at $482 million in 2023, highlighting significant investment in scaling operations.
  • Viridian Therapeutics: From a modest $7.8 million in 2014, expenses reached $95 million in 2023, showcasing its dynamic growth trajectory.

This financial journey underscores the strategic priorities of these companies as they navigate the biotech landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025